Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib: Correspondence

British Journal of Dermatology

Volumn 162, Issue 3, 2010, Pages 697-699

  Donghi, D ^a   Dummer, R ^a   Cozzio, A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Angiosarcoma; Metastasis; Paclitaxel; Remission; Sorafenib

Indexed keywords

PACLITAXEL; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

AGE; AGED; ANGIOSARCOMA; CANCER REGRESSION; CASE REPORT; CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; LETTER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; SEX RATIO; SKIN BIOPSY; SKIN CANCER; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; HEAD AND NECK NEOPLASMS; HEMANGIOSARCOMA; REMISSION; SKIN NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; HEAD AND NECK NEOPLASMS; HEMANGIOSARCOMA; HUMANS; MALE; NIACINAMIDE; PACLITAXEL; PHENYLUREA COMPOUNDS; PYRIDINES; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 76849117880     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09607.x     Document Type: Letter

References (10)

1. Pawlik TM, Paulino AF, Mcginn CJ et al. Cutaneous angiosarcoma of the scalp. Cancer 2003 98 : 1716 1726.
2. Mendenhall WM, Mendenhall CM, Werning JW et al. Cutaneous angiosarcoma. Am J Clin Oncol 2006 29 : 524 528.
3. Morgan MB, Swann M, Somach S et al. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol 2004 50 : 867 874.
4. Vogt T. Angiosarkom. Hautarzt 2008 59 : 237 251.
5. Abraham JA, Hornicek FJ, Kaufman AM et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007 14 : 1953 1967. Epub 2007 Mar 14.
6. Fury MG, Antonescu CR, Van Zee KJ et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005 11 : 241 247.
7. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004 64 : 7099 7109.
8. D'Adamo DR, Keohan M, Schuetze S et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007 25 (Suppl. 18S 10001.
9. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumours. Oncologist 2008 13 : 845 858. Epub 2008 Aug 11.
10. Jonasch E, Corn P, Ashe RG et al. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2007 25 : 260s.